70 related articles for article (PubMed ID: 8797590)
1. Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells.
Grove KL; Cheng YC
Cancer Res; 1996 Sep; 56(18):4187-91. PubMed ID: 8797590
[TBL] [Abstract][Full Text] [Related]
2. Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration.
Grove KL; Guo X; Liu SH; Gao Z; Chu CK; Cheng YC
Cancer Res; 1995 Jul; 55(14):3008-11. PubMed ID: 7606719
[TBL] [Abstract][Full Text] [Related]
3. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.
Kadhim SA; Bowlin TL; Waud WR; Angers EG; Bibeau L; DeMuys JM; Bednarski K; Cimpoia A; Attardo G
Cancer Res; 1997 Nov; 57(21):4803-10. PubMed ID: 9354442
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor activity of troxacitabine and camptothecin in selected human cancer cell lines.
Kim TE; Park SY; Hsu CH; Dutschman GE; Cheng YC
Mol Pharmacol; 2004 Aug; 66(2):285-92. PubMed ID: 15266019
[TBL] [Abstract][Full Text] [Related]
5. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
7. The impact of hypoxic treatment on the expression of phosphoglycerate kinase and the cytotoxicity of troxacitabine and gemcitabine.
Lam W; Leung CH; Bussom S; Cheng YC
Mol Pharmacol; 2007 Sep; 72(3):536-44. PubMed ID: 17565005
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
9. Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma.
Lam W; Bussom S; Cheng YC
Mol Cancer Ther; 2009 Feb; 8(2):415-23. PubMed ID: 19208827
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetics of beta-L-dioxolane-cytidine, a novel anticancer agent, in rats.
Moore LE; Boudinot FD; Chu CK
Cancer Chemother Pharmacol; 1997; 39(6):532-6. PubMed ID: 9118465
[TBL] [Abstract][Full Text] [Related]
11. Beta-L-1,3-dioxolane-cytidine: a novel nucleoside that inhibits proliferation and induces differentiation of keratinocytes in vitro.
Schwartz PM; Haggerty JG; Cheng YC
Skin Pharmacol Appl Skin Physiol; 1998; 11(4-5):207-13. PubMed ID: 9885404
[TBL] [Abstract][Full Text] [Related]
12. A novel action of human apurinic/apyrimidinic endonuclease: excision of L-configuration deoxyribonucleoside analogs from the 3' termini of DNA.
Chou KM; Kukhanova M; Cheng YC
J Biol Chem; 2000 Oct; 275(40):31009-15. PubMed ID: 10906132
[TBL] [Abstract][Full Text] [Related]
13. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
Gourdeau H; Leblond L; Hamelin B; Dong K; Ouellet F; Boudreau C; Custeau D; Richard A; Gilbert MJ; Jolivet J
Clin Cancer Res; 2004 Nov; 10(22):7692-702. PubMed ID: 15570003
[TBL] [Abstract][Full Text] [Related]
14. Apurinic/apyrimidinic endonuclease-1 protein level is associated with the cytotoxicity of L-configuration deoxycytidine analogs (troxacitabine and beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine) but not D-configuration deoxycytidine analogs (gemcitabine and beta-D-arabinofuranosylcytosine).
Lam W; Park SY; Leung CH; Cheng YC
Mol Pharmacol; 2006 May; 69(5):1607-14. PubMed ID: 16481390
[TBL] [Abstract][Full Text] [Related]
15. The role of human nucleoside transporters in cellular uptake of 4'-thio-beta-D-arabinofuranosylcytosine and beta-D-arabinosylcytosine.
Clarke ML; Damaraju VL; Zhang J; Mowles D; Tackaberry T; Lang T; Smith KM; Young JD; Tomkinson B; Cass CE
Mol Pharmacol; 2006 Jul; 70(1):303-10. PubMed ID: 16617163
[TBL] [Abstract][Full Text] [Related]
16. Pannarin inhibits cell growth and induces cell death in human prostate carcinoma DU-145 cells.
Russo A; Piovano M; Lombardo L; Vanella L; Cardile V; Garbarino J
Anticancer Drugs; 2006 Nov; 17(10):1163-9. PubMed ID: 17075315
[TBL] [Abstract][Full Text] [Related]
17. Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo.
Rabbani SA; Harakidas P; Bowlin T; Attardo G
Cancer Res; 1998 Aug; 58(15):3461-5. PubMed ID: 9699681
[TBL] [Abstract][Full Text] [Related]
18. Tumor-targeted apoptosis by a novel spermine analogue, 1,12-diaziridinyl-4,9-diazadodecane, results in therapeutic efficacy and enhanced radiosensitivity of human prostate cancer.
Eiseman JL; Rogers FA; Guo Y; Kauffman J; Sentz DL; Klinger MF; Callery PS; Kyprianou N
Cancer Res; 1998 Nov; 58(21):4864-70. PubMed ID: 9809992
[TBL] [Abstract][Full Text] [Related]
19. In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.
Radi M; Adema AD; Daft JR; Cho JH; Hoebe EK; Alexander LE; Peters GJ; Chu CK
J Med Chem; 2007 May; 50(9):2249-53. PubMed ID: 17419604
[TBL] [Abstract][Full Text] [Related]
20. Formation of a novel topotecan metabolite in the hormone-independent human prostate carcinoma cell lines DU-145 and PC-3.
Platzer P; Herzog W; Thalhammer T; Hamilton G; Haberl I; Jäger W
Anticancer Res; 1998; 18(4A):2737-41. PubMed ID: 9703938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
